Drugs in R & D

, Volume 2, Issue 6, pp 393–396 | Cite as


GVG, MDL 71754, RMI 71754, Sabril, Sabrilex, γ-Vinyl-GABA
Section 1: Migraine Adis R&D Profile


Adis International Limited Vigabatrin Visual Field Defect Bodyweight Gain Visual Field Constriction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arndt CF, Derambure P, Defoort S, et al. Is visual impairment related to vigabatrin reversible? Epilepsia 1999; 40 Suppl. 2: 256Google Scholar
  2. 2.
    Paul SR, Krauss GL, Johnson MA, et al. Progression and recovery of visual function in patients treated with vigabatrin. Epilepsia 1999; 40 Suppl. 2: 287–8Google Scholar
  3. 3.
    HMR Sabril associated with visual field defects, U.K. letter advises (Pink Sheet). FDC Reports — Prescription Pharmaceuticals and Biotechnology 1998 Apr 14; 60: 15Google Scholar
  4. 4.
    Nousiainen I, Kalviainen R, Mantyjarvi M, et al. Prevalence of concentric visual field constriction in adult epilepsy patients with vigabatrin treatment. Neurology 1999 Apr 12; 52 Suppl. 2: 235–6Google Scholar
  5. 5.
    Bjelajac A, Gautam M, Logan WJ. Vigabatrin and ophthalmologic abnormalities in pediatric patients. Neurology 1999 Apr 12; 52 Suppl. 2: 236Google Scholar
  6. 6.
    Wilton LV, Stephens MDB, Mann RD. Interim report on the incidence of visual field defects in patients on long term vigabatrin therapy. Pharmacoepidemiol Drug Saf 1999 Apr; 8 Suppl. 1: 9–14CrossRefGoogle Scholar
  7. 7.
    Lawden MC, Eke T, Degg C, et al. Visual field constriction associated with vigabatrin treatment. Epilepsia 1999; 40 Suppl. 2: 256–7Google Scholar
  8. 8.
    Zamponi N, Tavoni MA, Porfiri L, et al. Visual field defects associated with vigabatrin (VGB)monotherapy in asymptomatic children: preliminary results. Epilepsia 1999; 40 Suppl. 2: 70Google Scholar
  9. 9.
    Schmidt T, Schmitz B, Jokiel B, et al. Constriction of the visual field in epilepsy patients taking vigabatrin and other antiepileptic drugs. Epilepsia 1999; 40 Suppl. 2: 256Google Scholar
  10. 10.
    Wilton LV, Stephens MDB, Mann RD. Visual field defect associated with vigabatrin: observational cohort study. BMJ 1999; 319: 1165–6PubMedCrossRefGoogle Scholar
  11. 11.
    Naumann M, Supprian T, Kornhuber J, et al. Bipolar affective psychosis after vigabatrin. Lancet 1994 Mar 5; 343: 606–7PubMedCrossRefGoogle Scholar
  12. 12.
    Aldenkamp AP, Vermeulen J, Mulder OG, et al. gamma-Vinyl- GABA (vigabatrin) and mood disturbances. Epilepsia 1994 Sep–Oct; 35: 999–1004PubMedCrossRefGoogle Scholar
  13. 13.
    Sastre-Garau P, Thomas P, Beaussart M, et al. Manic disorder following an association of vigabatrin-clomipramine. Encephale 1994 May–Jun; 20: 363PubMedGoogle Scholar
  14. 14.
    Neufeld MY, Vishnevska S. Vigabatrin and multifocal myoclonus in adults with partial seizures. Clin Neuropharmacol 1995 Jun; 18: 280–3PubMedCrossRefGoogle Scholar
  15. 15.
    Gil R, Neau JP. Rapid aggravation of aphasia by vigabatrin. J Neurol 1995 Mar; 242: 251–2PubMedCrossRefGoogle Scholar
  16. 16.
    de Feo MR, Mercarelli O, Marciani MG, et al. Vigabatrinmonotherapy in newly diagnosed partial epilepsy: an open multicentre Italian pilot study. Med Sci Res 1998 Apr; 26: 283–4Google Scholar
  17. 17.
    Chadwick D, Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999 Jul 3; 354: 13–9PubMedCrossRefGoogle Scholar
  18. 18.
    Gobbi G, Pini A, Bertani G, et al. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy Res 1999 May; 35: 29–37PubMedCrossRefGoogle Scholar
  19. 19.
    Ghose K, Niven B, McLeod A, et al. Vigabatrin in the prophylaxis of drug resistant migraine: a double blind crossover comparison with placebo. Cephalalgia 1996 Aug; 16: 367Google Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations